Understand disease progression, treatment behavior, and real-world outcomes

Longitudinal, person-level real-world data captured directly from individuals to support research, evidence generation, and decision-making across the product lifecycle.

Understand disease progression and behavior over time

• Analyze longitudinal patterns across symptoms, function, and daily context
• Observe health outside clinical encounters
• Understand disease progression beyond episodic claims data

Inform portfolio, pipeline, and evidence decisions

• Evaluate hypotheses using longitudinal, real-world data
• Identify and prioritize populations based on behavior and outcomes
• Strengthen investment decisions with contextual evidence

Enable advanced modeling and evidence development

• Define subgroups beyond demographics and claims
• Compare behavior and outcomes across populations over time
• Inform model development, protocol design, and commercial strategy

The Evidation Community: an ongoing connection to 5M people

*Varies by population, protocol, and length of program; many of our recent programs have seen 90%+ engagement

Conversion rate for “click to read” offers once offer is seen

Scaled

1M+ Members have participated in research

97% of U.S. zip codes represented

Characterized

1.3B+ data points collected daily

100+ conditions represented

Engaged

90% average program engagement*

89% average response to content seen in app**

What you can understand with this data

Analyze disease progression, treatment behavior, and real-world outcomes using longitudinal, multimodal data collected over time.

Longitudinal, person-level data across behavior and outcomes: Access rich, historical data unified at the individual level, capturing how health, treatment, and behavior evolve over time across multiple dimensions. Data includes:

• Patient-reported outcomes and survey data
• Behavioral and functional measures
• Connected device and wearable data
• Clinical data
• Molecular data, where available

Deep population characterization for targeted analysis: Access condition-specific cohorts enriched with demographic, behavioral, and health attributes to identify subgroups, segment populations, and understand variation in outcomes.

Structured for analytics, modeling, and evidence generation: Receive datasets formatted for advanced analytics, model development, and secondary data linkage, enabling analysis of progression, behavior, and outcomes over time.

Flexible access to longitudinal data: License de-identified, individual-level datasets as a one-time extract or through a subscription model with recurring updates and continuous data enrichment.

See how we drive success for our customers:

Identifying and addressing gaps in the patient experience

Myovant uncovered significant unmet needs among individuals with uterine fibroids (UF) in a direct-to-patient 4-month study with 350 women living with UF.

92% weekly survey completion

85% daily survey completion

READ!

FluSmart participants receive alerts and nudges to seek care

In partnership with BARDA, Evidation developed and deployed a flu monitoring program, FluSmart, within the Evidation Community to collect rich, longitudinal data and activate high-risk participants into research and care.

200K+ individuals partcipated in FluSmart

90%+ gagement rate

READ!

Members who suffer from migraines receive personal health feedback

Evidation developed, and deployed, MigraineSmart, a symptom tracking health program that collects direct-from-participant data and provides educational content and personalized insights to participants, helping them better understand and manage their migraines.

3K+ individuals participated in the MigraineSmart program

48% said that tracking helps them better understand symptom patterns and migraine triggers

READ!

Therapeutic experience

Autoimmune

Cardiology

Dermatology

Mental Health

Metabolic

Neurology

Respiratory

Women's Health

Vaccines and Infectious Diseases

Who we work with

Evidation partners include top biopharma companies, as well as consumer health companies, technology companies, non-profit organizations, and government agencies.